Search T Helper/CD4+ T-Cell Epitope Database

Found 34 matching records:

Displaying record number 201953

Download this epitope record as JSON.

HXB2 Location	Gag(167-176) p24(35-44) DNA(1288..1317)	Gag Epitope Map
Author Location	Gag(167-176)
Epitope	`EVIPMFTALS`	Epitope Alignment
Epitope Name	HC003J
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to EVIPMFTALS (ES10/HC003J), as well as related 15-mer EVIPMFTALSEGATP and shorter peptides, EVIPMFTALSEGAT (ET14/HC003B), EVIPMFTALSEGA (EA13/HC003D), EVIPMFTALSEG (EG12/HC003F), and EVIPMFTALSE (EE11/HC003H). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at EVIPMFTALS and FTALSEGAT for DRB1*0401 and VIPMPT and LSEGAT for DRB1*0701, both of which are predicted HLA.

References

Borthwick2020 Nicola Borthwick, Sandra Silva-Arrieta, Anuska Llano, Masafumi Takiguchi, Christian Brander, and Tomáš Hanke. Novel Nested Peptide Epitopes Recognized by CD4+ T Cells Induced by HIV-1 Conserved-Region Vaccines. Vaccines, 8(1), 16 Jan 2020. PubMed ID: 31963212. Show all entries for this paper.

Displaying record number 201952

Download this epitope record as JSON.

HXB2 Location	Gag(167-177) p24(35-45) DNA(1288..1320)	Gag Epitope Map
Author Location	Gag(167-177)
Epitope	`EVIPMFTALSE`	Epitope Alignment
Epitope Name	HC003H
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to EVIPMFTALSE (EE11/HC003H), as well as related 15-mer EVIPMFTALSEGATP and shorter peptides, EVIPMFTALSEGAT (ET14/HC003B), EVIPMFTALSEGA (EA13/HC003D), EVIPMFTALSEG (EG12/HC003F), and EVIPMFTALS (ES10/HC003J). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at EVIPMFTALS and FTALSEGAT for DRB1*0401 and VIPMPT and LSEGAT for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201951

Download this epitope record as JSON.

HXB2 Location	Gag(167-178) p24(35-46) DNA(1288..1323)	Gag Epitope Map
Author Location	Gag(167-178)
Epitope	`EVIPMFTALSEG`	Epitope Alignment
Epitope Name	HC003F
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to EVIPMFTALSEG (EG12/HC003F), as well as related 15-mer EVIPMFTALSEGATP and shorter peptides, EVIPMFTALSEGAT (ET14/HC003B), EVIPMFTALSEGA (EA13/HC003D), EVIPMFTALSE (EE11/HC003H), and EVIPMFTALS (ES10/HC003J). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at EVIPMFTALS and FTALSEGAT for DRB1*0401 and VIPMPT and LSEGAT for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201950

Download this epitope record as JSON.

HXB2 Location	Gag(167-179) p24(35-47) DNA(1288..1326)	Gag Epitope Map
Author Location	Gag(167-179)
Epitope	`EVIPMFTALSEGA`	Epitope Alignment
Epitope Name	HC003D
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to EVIPMFTALSEGA (EA13/HC003D), as well as related 15-mer EVIPMFTALSEGATP and shorter peptides, EVIPMFTALSEGAT (ET14/HC003B), EVIPMFTALSEG (EG12/HC003F), EVIPMFTALSE (EE11/HC003H), and EVIPMFTALS (ES10/HC003J). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at EVIPMFTALS and FTALSEGAT for DRB1*0401 and VIPMPT and LSEGAT for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201949

Download this epitope record as JSON.

HXB2 Location	Gag(167-180) p24(35-48) DNA(1288..1329)	Gag Epitope Map
Author Location	Gag(167-180)
Epitope	`EVIPMFTALSEGAT`	Epitope Alignment
Epitope Name	HC003B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to EVIPMFTALSEGAT (ET14/HC003B), as well as related 15-mer EVIPMFTALSEGATP and shorter peptides, EVIPMFTALSEGA (EA13/HC003D), EVIPMFTALSEG (EG12/HC003F), EVIPMFTALSE (EE11/HC003H), and EVIPMFTALS (ES10/HC003J). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at EVIPMFTALS and FTALSEGAT for DRB1*0401 and VIPMPT and LSEGAT for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201948

Download this epitope record as JSON.

HXB2 Location	Gag(167-181) p24(35-49) DNA(1288..1332)	Gag Epitope Map
Author Location	Gag(167-181)
Epitope	`EVIPMFTALSEGATP`	Epitope Alignment
Epitope Name	HC003
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to 15-mer EVIPMFTALSEGATP as well as shorter peptides, EVIPMFTALSEGAT (ET14/HC003B), EVIPMFTALSEGA (EA13/HC003D), EVIPMFTALSEG (EG12/HC003F), EVIPMFTALSE (EE11/HC003H), and EVIPMFTALS (ES10/HC003J). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at EVIPMFTALS and FTALSEGAT for DRB1*0401 and VIPMPT and LSEGAT for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201957

Download this epitope record as JSON.

HXB2 Location	Gag(269-281) p24(137-149) DNA(1594..1632)	Gag Epitope Map
Author Location	Gag(269-281)
Epitope	`GLNKIVRMYSPVS`	Epitope Alignment
Epitope Name	HC017D
Subtype	A, B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to GLNKIVRMYSPVS (GS13/HC017D), as well as the 15-mer GLNKIVRMYSPVSIL and shorter peptides, LNKIVRMYSPVSIL (HC017A), NKIVRMYSPVSIL (HC017C), GLNKIVRMYSPVSI (HC017B), and KIVRMYSPVSIL (KL11/HC017E). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at LNKIVRMYS for DRB1*0401 and IVRMYS for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201956

Download this epitope record as JSON.

HXB2 Location	Gag(269-282) p24(137-150) DNA(1594..1635)	Gag Epitope Map
Author Location	Gag(269-282)
Epitope	`GLNKIVRMYSPVSI`	Epitope Alignment
Epitope Name	HC017B
Subtype	A, B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to GLNKIVRMYSPVSI (HC017B), as well as the 15-mer GLNKIVRMYSPVSIL and shorter peptides, LNKIVRMYSPVSIL (HC017A), NKIVRMYSPVSIL (HC017C), GLNKIVRMYSPVS (GS13/HC017D), and KIVRMYSPVSIL (KL11/HC017E). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at LNKIVRMYS for DRB1*0401 and IVRMYS for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201947

Download this epitope record as JSON.

HXB2 Location	Gag(269-283) p24(137-151) DNA(1594..1638)	Gag Epitope Map
Author Location	Gag(269-283)
Epitope	`GLNKIVRMYSPVSIL`	Epitope Alignment
Epitope Name	HC017
Subtype	A, B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to 15-mer GLNKIVRMYSPVSIL as well as shorter peptides, LNKIVRMYSPVSIL (HC017A), GLNKIVRMYSPVSI (HC017B), NKIVRMYSPVSIL (HC017C), GLNKIVRMYSPVS (GS13 or HC017D), and KIVRMYSPVSIL (KL11 or HC017E). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at LNKIVRMYS for DRB1*0401 and IVRMYS for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201954

Download this epitope record as JSON.

HXB2 Location	Gag(270-283) p24(138-151) DNA(1597..1638)	Gag Epitope Map
Author Location	Gag(270-283)
Epitope	`LNKIVRMYSPVSIL`	Epitope Alignment
Epitope Name	HC017A
Subtype	A, B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to LNKIVRMYSPVSIL (HC017A), as well as the 15-mer GLNKIVRMYSPVSIL and shorter peptides, GLNKIVRMYSPVSI (HC017B), NKIVRMYSPVSIL (HC017C), GLNKIVRMYSPVS (GS13/HC017D), and KIVRMYSPVSIL (KL11/HC017E). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at LNKIVRMYS for DRB1*0401 and IVRMYS for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201955

Download this epitope record as JSON.

HXB2 Location	Gag(271-283) p24(139-151) DNA(1600..1638)	Gag Epitope Map
Author Location	Gag(269-283)
Epitope	`NKIVRMYSPVSIL`	Epitope Alignment
Epitope Name	HC017C
Subtype	A, B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to NKIVRMYSPVSIL (HC017C), as well as the 15-mer GLNKIVRMYSPVSIL and shorter peptides, LNKIVRMYSPVSIL (HC017A), GLNKIVRMYSPVSI (HC017B), GLNKIVRMYSPVS (GS13/HC017D), and KIVRMYSPVSIL (KL11/HC017E). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at LNKIVRMYS for DRB1*0401 and IVRMYS for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201958

Download this epitope record as JSON.

HXB2 Location	Gag(272-283) p24(140-151) DNA(1603..1638)	Gag Epitope Map
Author Location	Gag(272-283)
Epitope	`KIVRMYSPVSIL`	Epitope Alignment
Epitope Name	HC017E
Subtype	A, B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID418: A02:01, A24:02, B07:02, B27:05, C01:02, C07:02, DQB103:01, DQB103:03, DRB104:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 418 had a stimulatory response to KIVRMYSPVSIL (KL11/HC017E), as well as the 15-mer GLNKIVRMYSPVSIL and shorter peptides, LNKIVRMYSPVSIL (HC017A), NKIVRMYSPVSIL (HC017C), GLNKIVRMYSPVSI (HC017B), and GLNKIVRMYSPVS (GS13/HC017D). In addition to IFN-γ, TNF-α was also produced.
Epitope Location Finder tool predicts epitope cores at LNKIVRMYS for DRB1*0401 and IVRMYS for DRB1*0701, both of which are predicted HLA.

References

Displaying record number 201962

Download this epitope record as JSON.

HXB2 Location	Pol(270-282) RT(115-127) DNA(2892..2930)	Pol Epitope Map
Author Location	Pol(270-282)
Epitope	`YFSVPLDEGFRKY`	Epitope Alignment
Epitope Name	HC078D
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 (DBR1*01:01, DRB1*07:01) had a stimulatory response to YFSVPLDEGFRKY (HC078D), 15-mer YFSVPLDEGFRKYTA as well as shorter peptides, FSVPLDEGFRKYTA (HC078A), SVPLDEGFRKYTA (HC078C), VPLDEGFRKYTA (VA12/HC078E), and PLDEGFRKYTA (HC078G). In addition to IFN-γ, TNF-α was also produced. VA12 was the strongest IFN-γ stimulating peptide and PA11, the weakest, producing substantial TNF-α, indicating that these are potentially different epitopes stimulating different Helper T cell populations.

References

Displaying record number 201959

Download this epitope record as JSON.

HXB2 Location	Pol(270-284) RT(115-129) DNA(2892..2936)	Pol Epitope Map
Author Location	Pol(270-284)
Epitope	`YFSVPLDEGFRKYTA`	Epitope Alignment
Epitope Name	HC078
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 (DBR1*01:01, DRB1*07:01) had a stimulatory response to 15-mer YFSVPLDEGFRKYTA as well as shorter peptides, FSVPLDEGFRKYTA (HC078A), SVPLDEGFRKYTA (HC078C), YFSVPLDEGFRKY (HC078D), VPLDEGFRKYTA (VA12/HC078E), and PLDEGFRKYTA (HC078G). In addition to IFN-γ, TNF-α was also produced. VA12 was the strongest IFN-γ stimulating peptide and PA11, the weakest, producing substantial TNF-α, indicating that these are potentially different epitopes stimulating different Helper T cell populations.

References

Displaying record number 201960

Download this epitope record as JSON.

HXB2 Location	Pol(271-284) RT(116-129) DNA(2895..2936)	Pol Epitope Map
Author Location	Pol(271-284)
Epitope	`FSVPLDEGFRKYTA`	Epitope Alignment
Epitope Name	HC078A
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 (DBR1*01:01, DRB1*07:01) had a stimulatory response to FSVPLDEGFRKYTA (HC078A), 15-mer YFSVPLDEGFRKYTA as well as shorter peptides, SVPLDEGFRKYTA (HC078C), YFSVPLDEGFRKY (HC078D), VPLDEGFRKYTA (VA12/HC078E), and PLDEGFRKYTA (HC078G). In addition to IFN-γ, TNF-α was also produced. VA12 was the strongest IFN-γ stimulating peptide and PA11, the weakest, producing substantial TNF-α, indicating that these are potentially different epitopes stimulating different Helper T cell populations.

References

Displaying record number 201961

Download this epitope record as JSON.

HXB2 Location	Pol(272-284) RT(117-129) DNA(2898..2936)	Pol Epitope Map
Author Location	Pol(272-284)
Epitope	`SVPLDEGFRKYTA`	Epitope Alignment
Epitope Name	HC078C
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 (DBR1*01:01, DRB1*07:01) had a stimulatory response to SVPLDEGFRKYTA (HC078C), 15-mer YFSVPLDEGFRKYTA as well as shorter peptides, FSVPLDEGFRKYTA (HC078A), YFSVPLDEGFRKY (HC078D), VPLDEGFRKYTA (VA12/HC078E), and PLDEGFRKYTA (HC078G). In addition to IFN-γ, TNF-α was also produced. VA12 was the strongest IFN-γ stimulating peptide and PA11, the weakest, producing substantial TNF-α, indicating that these are potentially different epitopes stimulating different Helper T cell populations.

References

Displaying record number 201963

Download this epitope record as JSON.

HXB2 Location	Pol(273-284) RT(118-129) DNA(2901..2936)	Pol Epitope Map
Author Location	Pol(273-284)
Epitope	`VPLDEGFRKYTA`	Epitope Alignment
Epitope Name	HC078E, VA12
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 (DBR1*01:01, DRB1*07:01) had a stimulatory response to VPLDEGFRKYTA (VA12/HC078E), 15-mer YFSVPLDEGFRKYTA as well as shorter peptides, FSVPLDEGFRKYTA (HC078A), SVPLDEGFRKYTA (HC078C), YFSVPLDEGFRKY (HC078D), and PLDEGFRKYTA (HC078G). In addition to IFN-γ, TNF-α was also produced. VA12 was the strongest IFN-γ stimulating peptide and PA11, the weakest, producing substantial TNF-α, indicating that these are potentially different epitopes stimulating different Helper T cell populations.

References

Displaying record number 201972

Download this epitope record as JSON.

HXB2 Location	Pol(274-282) RT(119-127) DNA(2904..2930)	Pol Epitope Map
Author Location	Gag(274-284)
Epitope	`PLDEGFRKY`	Epitope Alignment
Epitope Name	HC079L
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 had a stimulatory response to FRKYTAFTIP (FP10/HC079I), 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, LDEGFRKYTAFTIP (HC079A), PLDEGFRKYTAFTI (HC079B), DEGFRKYTAFTIP (HC079C), PLDEGFRKYTAFT (HC079D), PLDEGFRKYTA (HC079H/HC078G/PA11), GFRKYTAFTIP (HC079G), and PLDEGFRKY (PY9/HC079L). In addition to IFN-γ, TNF-α was also produced but not for HC079B/D/H and L.
The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201964

Download this epitope record as JSON.

HXB2 Location	Pol(274-284) RT(119-129) DNA(2904..2936)	Pol Epitope Map
Author Location	Pol(274-284)
Epitope	`PLDEGFRKYTA`	Epitope Alignment
Epitope Name	HC078G, PA11, HC079H
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 (DBR1*01:01, DRB1*07:01) had a stimulatory response to PLDEGFRKYTA (HC078G/HC079H), 15-mer YFSVPLDEGFRKYTA as well as shorter peptides, FSVPLDEGFRKYTA (HC078A), SVPLDEGFRKYTA (HC078C), YFSVPLDEGFRKY (HC078D), and VPLDEGFRKYTA (VA12/HC078E). In addition to IFN-γ, TNF-α was also produced. VA12 was the strongest IFN-γ stimulating peptide and PA11, the weakest, producing substantial TNF-α, indicating that these are potentially different epitopes stimulating different Helper T cell populations.
VID 417 also had a stimulatory response to 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, LDEGFRKYTAFTIP (HC079A), PLDEGFRKYTAFTI (HC079B), DEGFRKYTAFTIP (HC079C), PLDEGFRKYTAFT (HC079D), GFRKYTAFTIP (HC079G), FRKYTAFTIP (FP10/HC079I), and KIVRMYSPVSIL (PY9/HC079L). The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201969

Download this epitope record as JSON.

HXB2 Location	Pol(274-286) RT(119-131) DNA(2904..2942)	Pol Epitope Map
Author Location	Gag(274-286)
Epitope	`PLDEGFRKYTAFT`	Epitope Alignment
Epitope Name	HC079D
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 had a stimulatory response to PLDEGFRKYTAFT (HC079D), 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, LDEGFRKYTAFTIP (HC079A), PLDEGFRKYTAFTI (HC079B), DEGFRKYTAFTIP (HC079C), GFRKYTAFTIP (HC079G), PLDEGFRKYTA (HC079H/HC078G/PA11), FRKYTAFTIP (FP10/HC079I), and PLDEGFRKY (PY9/HC079L). In addition to IFN-γ, TNF-α was also produced but not for HC079B/D/H and L.
The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201967

Download this epitope record as JSON.

HXB2 Location	Pol(274-287) RT(119-132) DNA(2904..2945)	Pol Epitope Map
Author Location	Gag(274-287)
Epitope	`PLDEGFRKYTAFTI`	Epitope Alignment
Epitope Name	HC079B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 had a stimulatory response to PLDEGFRKYTAFTI (HC079B), 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, LDEGFRKYTAFTIP (HC079A), DEGFRKYTAFTIP (HC079C), PLDEGFRKYTAFT (HC079D), GFRKYTAFTIP (HC079G), PLDEGFRKYTA (HC079H/HC078G/PA11), FRKYTAFTIP (FP10/HC079I), and PLDEGFRKY (PY9/HC079L). In addition to IFN-γ, TNF-α was also produced but not for HC079B/D/H and L.
The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201965

Download this epitope record as JSON.

HXB2 Location	Pol(274-288) RT(119-133) DNA(2904..2948)	Pol Epitope Map
Author Location	Gag(274-288)
Epitope	`PLDEGFRKYTAFTIP`	Epitope Alignment
Epitope Name	HC079
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 had a stimulatory response to 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, LDEGFRKYTAFTIP (HC079A), PLDEGFRKYTAFTI (HC079B), DEGFRKYTAFTIP (HC079C), PLDEGFRKYTAFT (HC079D), GFRKYTAFTIP (HC079G), PLDEGFRKYTA (HC079H), FRKYTAFTIP (FP10/HC079I), and PLDEGFRKY (PY9/HC079L). In addition to IFN-γ, TNF-α was also produced but not for HC079B/D/H and L.
The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201966

Download this epitope record as JSON.

HXB2 Location	Pol(275-288) RT(120-133) DNA(2907..2948)	Pol Epitope Map
Author Location	Gag(275-288)
Epitope	`LDEGFRKYTAFTIP`	Epitope Alignment
Epitope Name	HC079A
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 had a stimulatory response to LDEGFRKYTAFTIP (HC079A), 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, PLDEGFRKYTAFTI (HC079B), DEGFRKYTAFTIP (HC079C), PLDEGFRKYTAFT (HC079D), GFRKYTAFTIP (HC079G), PLDEGFRKYTA (HC079H/HC078G/PA11), FRKYTAFTIP (FP10/HC079I), and PLDEGFRKY (PY9/HC079L). In addition to IFN-γ, TNF-α was also produced but not for HC079B/D/H and L.
The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201968

Download this epitope record as JSON.

HXB2 Location	Pol(276-288) RT(121-133) DNA(2910..2948)	Pol Epitope Map
Author Location	Gag(276-288)
Epitope	`DEGFRKYTAFTIP`	Epitope Alignment
Epitope Name	HC079C
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 had a stimulatory response to DEGFRKYTAFTIP (HC079C), 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, LDEGFRKYTAFTIP (HC079A), PLDEGFRKYTAFTI (HC079B), PLDEGFRKYTAFT (HC079D), GFRKYTAFTIP (HC079G), PLDEGFRKYTA (HC079H/HC078G/PA11), FRKYTAFTIP (FP10/HC079I), and PLDEGFRKY (PY9/HC079L). In addition to IFN-γ, TNF-α was also produced but not for HC079B/D/H and L.
The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201970

Download this epitope record as JSON.

HXB2 Location	Pol(278-288) RT(123-133) DNA(2916..2948)	Pol Epitope Map
Author Location	Gag(278-288)
Epitope	`GFRKYTAFTIP`	Epitope Alignment
Epitope Name	HC079G
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 had a stimulatory response to GFRKYTAFTIP (HC079G), 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, LDEGFRKYTAFTIP (HC079A), PLDEGFRKYTAFTI (HC079B), DEGFRKYTAFTIP (HC079C), PLDEGFRKYTAFT (HC079D), PLDEGFRKYTA (HC079H/HC078G/PA11), FRKYTAFTIP (FP10/HC079I), and PLDEGFRKY (PY9/HC079L). In addition to IFN-γ, TNF-α was also produced but not for HC079B/D/H and L.
The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201979

Download this epitope record as JSON.

HXB2 Location	Pol(278-289) RT(123-134) DNA(2916..2951)	Pol Epitope Map
Author Location	Gag(278-289)
Epitope	`GFRKYTAFTIPS`	Epitope Alignment
Epitope Name	HC080F
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 411 (DRB1*03:01, DR1*09:01) had a stimulatory response to GFRKYTAFTIPS (HC080F/GS12), 15-mer GFRKYTAFTIPSINN as well as shorter peptides, FRKYTAFTIPSINN (HC080A/FN14), GFRKYTAFTIPSIN (HC080B), RKYTAFTIPSINN (HC080C), GFRKYTAFTIPSI (HC080D), KYTAFTIPSINN (HC080E) and YTAFTIPSINN (HC080G/YN11). In addition to IFN-γ, TNF-α was also produced.
Overlapping peptide, FRKYTAFTIPSINNE, is known to contain a DR supermotif.

References

Displaying record number 201977

Download this epitope record as JSON.

HXB2 Location	Pol(278-290) RT(123-135) DNA(2916..2954)	Pol Epitope Map
Author Location	Gag(278-290)
Epitope	`GFRKYTAFTIPSI`	Epitope Alignment
Epitope Name	HC080D
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 411 (DRB1*03:01, DR1*09:01) had a stimulatory response to GFRKYTAFTIPSI (HC080D), 15-mer GFRKYTAFTIPSINN as well as shorter peptides, FRKYTAFTIPSINN (HC080A/FN14), GFRKYTAFTIPSIN (HC080B), RKYTAFTIPSINN (HC080C), KYTAFTIPSINN (HC080E), GFRKYTAFTIPS (HC080F/GS12) and YTAFTIPSINN (HC080G/YN11). In addition to IFN-γ, TNF-α was also produced.
Overlapping peptide, FRKYTAFTIPSINNE, is known to contain a DR supermotif.

References

Displaying record number 201975

Download this epitope record as JSON.

HXB2 Location	Pol(278-291) RT(123-136) DNA(2916..2957)	Pol Epitope Map
Author Location	Gag(278-291)
Epitope	`GFRKYTAFTIPSIN`	Epitope Alignment
Epitope Name	HC080B
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 411 (DRB1*03:01, DR1*09:01) had a stimulatory response to GFRKYTAFTIPSIN (HC080B), 15-mer GFRKYTAFTIPSINN as well as shorter peptides, FRKYTAFTIPSINN (HC080A/FN14), RKYTAFTIPSINN (HC080C), GFRKYTAFTIPSI (HC080D), KYTAFTIPSINN (HC080E), GFRKYTAFTIPS (HC080F/GS12) and YTAFTIPSINN (HC080G/YN11). In addition to IFN-γ, TNF-α was also produced.
Overlapping peptide, FRKYTAFTIPSINNE, is known to contain a DR supermotif.

References

Displaying record number 201973

Download this epitope record as JSON.

HXB2 Location	Pol(278-292) RT(123-137) DNA(2916..2960)	Pol Epitope Map
Author Location	Gag(278-292)
Epitope	`GFRKYTAFTIPSINN`	Epitope Alignment
Epitope Name	HC080
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 411 (DRB1*03:01, DR1*09:01) had a stimulatory response to 15-mer GFRKYTAFTIPSINN as well as shorter peptides, FRKYTAFTIPSINN (HC080A/FN14), GFRKYTAFTIPSIN (HC080B), RKYTAFTIPSINN (HC080C), GFRKYTAFTIPSI (HC080D), KYTAFTIPSINN (HC080E), GFRKYTAFTIPS (HC080F/GS12) and YTAFTIPSINN (HC080G/YN11). In addition to IFN-γ, TNF-α was also produced.
Overlapping peptide, FRKYTAFTIPSINNE, is known to contain a DR supermotif.

References

Displaying record number 201971

Download this epitope record as JSON.

HXB2 Location	Pol(279-288) RT(124-133) DNA(2919..2948)	Pol Epitope Map
Author Location	Gag(279-288)
Epitope	`FRKYTAFTIP`	Epitope Alignment
Epitope Name	HC079I
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID417: A03:01, A30:04, B35:01, B50:01, C04:01, C06:02, DQB102, DQB105, DRB101:01, DRB107:01, DRB4
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 417 had a stimulatory response to FRKYTAFTIP (FP10/HC079I), 15-mer PLDEGFRKYTAFTIP as well as shorter peptides, LDEGFRKYTAFTIP (HC079A), PLDEGFRKYTAFTI (HC079B), DEGFRKYTAFTIP (HC079C), PLDEGFRKYTAFT (HC079D), PLDEGFRKYTA (HC079H/HC078G/PA11), GFRKYTAFTIP (HC079G), and PLDEGFRKY (PY9/HC079L). In addition to IFN-γ, TNF-α was also produced but not for HC079B/D/H and L.
The minimum epitopes were FRKYTAFTIP (FP10/HC079I) and PLDEGFRKY (PY9/HC079L) with no known HLA binding prediction.

References

Displaying record number 201974

Download this epitope record as JSON.

HXB2 Location	Pol(279-292) RT(124-137) DNA(2919..2960)	Pol Epitope Map
Author Location	Gag(279-292)
Epitope	`FRKYTAFTIPSINN`	Epitope Alignment
Epitope Name	HC080A
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 411 (DRB1*03:01, DR1*09:01) had the strongest stimulatory response to FRKYTAFTIPSINN (HC080A/FN14), but other stimulatory responses to 15-mer GFRKYTAFTIPSINN as well as shorter peptides, GFRKYTAFTIPSIN (HC080B), RKYTAFTIPSINN (HC080C), GFRKYTAFTIPSI (HC080D), KYTAFTIPSINN (HC080E), GFRKYTAFTIPS (HC080F/GS12) and YTAFTIPSINN (HC080G/YN11). In addition to IFN-γ, TNF-α was also produced.
Overlapping peptide, FRKYTAFTIPSINNE, is known to contain a DR supermotif.

References

Displaying record number 201976

Download this epitope record as JSON.

HXB2 Location	Pol(280-292) RT(125-137) DNA(2922..2960)	Pol Epitope Map
Author Location	Gag(280-292)
Epitope	`RKYTAFTIPSINN`	Epitope Alignment
Epitope Name	HC080C
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 411 (DRB1*03:01, DR1*09:01) had a stimulatory response to RKYTAFTIPSINN (HC080C), 15-mer GFRKYTAFTIPSINN as well as shorter peptides, FRKYTAFTIPSINN (HC080A/FN14), GFRKYTAFTIPSIN (HC080B), GFRKYTAFTIPSI (HC080D), KYTAFTIPSINN (HC080E), GFRKYTAFTIPS (HC080F/GS12) and YTAFTIPSINN (HC080G/YN11). In addition to IFN-γ, TNF-α was also produced.
Overlapping peptide, FRKYTAFTIPSINNE, is known to contain a DR supermotif.

References

Displaying record number 201978

Download this epitope record as JSON.

HXB2 Location	Pol(281-292) RT(126-137) DNA(2925..2960)	Pol Epitope Map
Author Location	Gag(281-292)
Epitope	`KYTAFTIPSINN`	Epitope Alignment
Epitope Name	HC080E
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 411 (DRB1*03:01, DR1*09:01) had a stimulatory response to KYTAFTIPSINN (HC080E), 15-mer GFRKYTAFTIPSINN as well as shorter peptides, FRKYTAFTIPSINN (HC080A/FN14), GFRKYTAFTIPSIN (HC080B), RKYTAFTIPSINN (HC080C), GFRKYTAFTIPSI (HC080D), GFRKYTAFTIPS (HC080F/GS12) and YTAFTIPSINN (HC080G/YN11). In addition to IFN-γ, TNF-α was also produced.
Overlapping peptide, FRKYTAFTIPSINNE, is known to contain a DR supermotif.

References

Displaying record number 201980

Download this epitope record as JSON.

HXB2 Location	Pol(282-292) RT(127-137) DNA(2928..2960)	Pol Epitope Map
Author Location	Gag(282-292)
Epitope	`YTAFTIPSINN`	Epitope Alignment
Epitope Name	HC080G
Species (MHC/HLA)	human
Immunogen	vaccine
Patient MHC/HLA	VID411: A02:01, B08:01, B51:01, C03:03, C07:01, DQB102, DQB103:03, DRB103:01, DRB1*09:01, DRB3, DRB5
Country	United Kingdom
Experimental methods	CD4 T-cell Elispot - IFNγ, Intracellular cytokine staining
Keywords	vaccine-induced immune responses, CD4+ CTL

Vaccine Details

Vaccine type	non-replicating adenovirus, polyepitope, DNA prime with modified vaccinia Ankara (MVA) boost, HIVconsv
Vaccine strain	A clade, B clade, multiple epitope immunogen, C clade, D clade
Vaccine component	Env, Gag, Pol, Vif, other

Notes

HIVconsv vaccine consists of 14 highly conserved regions of HIV-1 Gag, Pol, Vif, Env across clades A, B, C and D. Two vaccine regimens, CM or DDDCM, (ChAdV — ChAdV63.HIVconsv; MVA — MVA.HIVconsv; DNA - pSG2.HIVconsv) were used in the HIV-CORE 002 trial comprising HIV-negative, low-risk individuals. 199 15-mer peptides overlapping by 11 amino acids, which spanned the entire HIVconsv protein were used to interrogate PBMC from subjects, 11 of whom responded in CD4+ T cell EliSpot screenings. Truncation studies of specific epitopes suggested that the peptide length and sequence variation (altered peptide ligands) can determine whether a peptide elicits a full (agonist) or partial (partial agonist) activation phenotype or inhibitory (antagonist) CD4+ T-cell response to a stimulatory peptide epitope. Delivery of HIVconsv out of the context of the whole virus by this potent vaccine regimen revealed many novel T-cell epitopes not previously identified due to subdominant responses and thus not recorded in the Los Alamos Immunology HIV database before.
Volunteer ID 411 (DRB1*03:01, DR1*09:01) had a stimulatory response to YTAFTIPSINN (HC080G/YN11), 15-mer GFRKYTAFTIPSINN as well as shorter peptides, FRKYTAFTIPSINN (HC080A/FN14), GFRKYTAFTIPSIN (HC080B), RKYTAFTIPSINN (HC080C), GFRKYTAFTIPSI (HC080D), KYTAFTIPSINN (HC080E) and GFRKYTAFTIPS (HC080F/GS12). In addition to IFN-γ, TNF-α was also produced.
Overlapping peptide, FRKYTAFTIPSINNE, is known to contain a DR supermotif.